Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?

Cells

Marika Nordberg²  Pia Forsberg²  Dag Nyman¹  Barbro H. Skogman³  Clara Nyberg¹  Jan Ernerudh⁴  Ingvar Eliasson⁵ 

[1] The Åland Borrelia Group, Åland, 22100 Mariehamn, Åland, Finland;Department of Clinical and Experimental Medicine, Infectious Medicine Faculty of Health Sciences, Linköping University, 581 83 Linköping, Sweden;Center for Clinical Research (CKF) Dalarna, 791 36 Falun, Sweden;Department of Clinical and Experimental Medicine, Clinical Immunology, Linköping University, S-581 83 Linköping, Sweden;Department of Laboratory Medicine, NÄL, 461 85 Trollhättan, Sweden;

关键词: Borrelia burgdorferi;    neuroborreliosis;    ELISPOT;    cerebrospinal fluid;    diagnostic test;    sensitivity;    specificity;   

DOI  :  10.3390/cells1020153

来源: mdpi

【 摘 要 】

The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.